AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05622240
Drug: 99mTc-MIRC213
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-MIRC213 were intravenous injected into the patients before the wholebody and SPECT/CT scans
Trial: NCT05022771
Drug: PMG1015 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1 of PMG1015
Trial: NCT05022771
Drug: PMG1015 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 2 of PMG1015
Trial: NCT05022771
Drug: PMG1015 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 3 of PMG1015
Trial: NCT05022771
Drug: PMG1015 Dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 4 of PMG1015
Trial: NCT05022771
Drug: PMG1015 Dose 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 5 of PMG1015
Trial: NCT05022771
Drug: PMG1015 Dose 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 6 of PMG1015
Trial: NCT05022771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match
Trial: NCT05022771
Drug: PMG1015 Dose 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 7 of PMG1015
Trial: NCT06241599
Drug: GP/PFLL+AK104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks).
Trial: NCT06241599
Drug: GP/PFLL+placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks).
Trial: NCT05582811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05201859
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An oral anticancer agent that can be converted into 5-Fu in vivo.
Trial: NCT05060666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An analogous number of tablets is administered for placebo:~* 5 tablets for 40-60 kg~* 6 tablets for 60-80 kg~* 8 tablets for \> 80 kg~The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin.
Trial: NCT05753878
Drug: HH-120 nasal spray, Part A cohort 2-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of HH-120 nasal spray.
Trial: NCT05753878
Drug: HH-120 nasal spray, Part A cohort 8-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HH-120 nasal spray.
Trial: NCT05753878
Drug: HH-120 nasal spray, Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HH-120 nasal spray, 10 times daily for 7 consecutive days.
Trial: NCT05769842
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same dose as propofol.
Trial: NCT04702555
Drug: VTS-K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
Trial: NCT05203419
Drug: MHS552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
Trial: NCT05203419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
Trial: NCT05291598
Drug: IV meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be administered meloxicam 30 mg IV push pre-operatively.
Trial: NCT05291598
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.
Trial: NCT06448312
Drug: SKB264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05504148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take placebo piece during for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day
Trial: NCT06242067
Drug: Trifluridine/tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
Trial: NCT06046495
Drug: PLB1004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLB1004 will be orally self-administered by the patient as a mono-therapy.
Trial: NCT05132699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
Trial: NCT06451211
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants
Trial: NCT04575857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the control arm will receive a pill packet with placebo x 18 months.
Trial: NCT05800444
Drug: BAY3283142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration as tablet.
Trial: NCT06552598
Drug: KD01(the recombinant oncolytic adenovirus)
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase Ia PART 1 (Dose Escalation Phase with Monotherapy): Subjects in each dose group will continue to undergo a 21-day assessment for Dose-Limiting Toxicity (DLT) after completing the first cycle of treatment (D1-5), totaling 26 days starting from D1.~Phase Ib PART 2 (Dose Expansion Phase with Monotherapy): Subjects will receive intratumoral injections, starting on D1. Further treatment will continue based on the patient's willingness, with a maximum of 5 administrations. The final administration will be followed by surgery 7-14 days later, until the patient is discharged.
Trial: NCT06360874
Drug: MAD_ND003_Dose 1
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
Trial: NCT06360874
Drug: MAD_ND003_Dose 2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
Trial: NCT06360874
Drug: MAD_ND003_Dose 3
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
Trial: NCT06360874
Drug: MAD_ placebo_Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 3
Trial: NCT06360874
Drug: Food effect_Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
Trial: NCT06360874
Drug: Food effect_Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
Trial: NCT05496491
Drug: Consolidation Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
Trial: NCT05955586
Drug: SPR720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPR720 1000 mg (250 mg\*4 capsules) will be administered orally.
Trial: NCT00005117
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06065267
Drug: sequential
RxNorm normalized name: TABLET, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week
Trial: NCT04901065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
Trial: NCT05726903
Drug: Depo-subQ Provera Injectable Product
RxNorm normalized name: depo-subQ provera Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC Injection at Home
Trial: NCT05909215
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes
Trial: NCT05078463
Drug: 0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
Trial: NCT04860661
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml normal saline
Trial: NCT05364905
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Trial: NCT05674045
Drug: EG017 3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG017 3mg/day Oral administration for 12 weeks, once daily
Trial: NCT05674045
Drug: EG017 6mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG017 6mg/day Oral administration for 12 weeks, once daily
Trial: NCT05475821
Drug: Placebo for ABBV-990
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05943327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT04699604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06291103
Drug: Conversion to Belatacep
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.
Trial: NCT06416956
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will record infant\&#39;s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.
Trial: NCT05012319
Drug: to be given as a treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric Oxide Nasal Spray Enovid
Trial: NCT05518734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-708 for IV administration.
Trial: NCT04975971
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
Trial: NCT06121934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: visually matched placebo 2 capsule t.i.d for 5 days
Trial: NCT05388435
Drug: SKL27969
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
Trial: NCT04304755
Drug: Zoledronic Acid 5 MG in 5 ML Injection
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid
Trial: NCT04967508
Drug: Stelara® (Ustekinumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.
Trial: NCT05329155
Drug: Heparin Sodium Injection
RxNorm normalized name: Heparin Sodium Injection
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin Sodium Injection (100U/Kg body weight)
Trial: NCT04975269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05895513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive Comparator
Trial: NCT05060991
Drug: Reduction in antimetabolite immunosuppression
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination
Trial: NCT04710524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID for 13 weeks
Trial: NCT04710524
Drug: FM101 150 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FM101 (150 mg) BID for 13 weeks
Trial: NCT04710524
Drug: FM101 300 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FM101 (300 mg) BID for 13 weeks
Trial: NCT04647227
Drug: coagulation factor VIIa [recombinant]-jncw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a transgenically produced, activated, recombinant, human factor VII (rhFVIIa) protein with the brand name of SEVENFACT®. This protein is a clotting factor in the coagulation cascade that is produced in and purified from the milk of transgenic rabbits. SEVENFACT is approved for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.
Trial: NCT06205329
Drug: WPV01 Dose 1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPV01 Dose 1-4 or Placebo on day 1
Trial: NCT06205329
Drug: WPV01 Dose 9-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPV01 Dose 9-12 or Placebo from day 1 to day 6
Trial: NCT06239272
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate and High-risk An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Intermediate, High-risk Into the vein (IV) over about 1 hour, 2 doses, days 1 and 2
Trial: NCT06580002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06388941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally
Trial: NCT05763199
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy will be administered per standard of care.
Trial: NCT05151471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05573464
Drug: BGF MDI HFO 320/14.4/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate
Trial: NCT05762952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules formulated by pharmacy to be indistinguishable from active drug
Trial: NCT04906408
Drug: Traditional
RxNorm normalized name: Midol Traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisions will be dressed with bacitracin/xeroform
Trial: NCT05064085
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
Trial: NCT06343805
Drug: AJ1-11095
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type II JAK2 Inhibitor
Trial: NCT04948333
Drug: ABL001 40mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of 40 mg will be taken orally twice a day (BID)
Trial: NCT04948333
Drug: ABL001 200mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five tablets of 40 mg will be taken orally once a day (QD)
Trial: NCT05528224
Drug: conventional medical treatment (TAU)
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
Trial: NCT05728671
Drug: IP2015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT05624450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of matching placebo on Day 1.
Trial: NCT05819138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide placebo injection
Trial: NCT06118580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape-flavored drink
Trial: NCT06193486
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
Trial: NCT05133804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to Reboxetine
Trial: NCT05133804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to Ritalin
Trial: NCT02004782
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
Trial: NCT02004782
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
Trial: NCT05209165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo and intake visit for VA MOVE
Trial: NCT04804033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo softgel capsule.
Trial: NCT05097989
Drug: ALXN2050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT05097989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT02497638
Drug: Placebo (corresponding to atorvastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet (corresponding to atorvastatin) once daily until progression.
Trial: NCT05282446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching tablet
Trial: NCT05536141
Drug: casdatifan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm